Cargando…
Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
BACKGROUND: Canine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was evaluated...
Autores principales: | Geurden, Thomas, Six, Robert, Becskei, Csilla, Maeder, Steven, Lloyd, Anne, Mahabir, Sean, Fourie, Josephus, Liebenberg, Julian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588728/ https://www.ncbi.nlm.nih.gov/pubmed/28877743 http://dx.doi.org/10.1186/s13071-017-2358-3 |
Ejemplares similares
-
Comparative speed of kill of oral treatments with Simparica(TM)(sarolaner) and Bravecto®(fluralaner) against induced infestations of Rhipicephalus sanguineus on dogs
por: Becskei, Csilla, et al.
Publicado: (2016) -
Immediate and persistent efficacy of sarolaner (Simparica™) against Haemaphysalis elliptica on dogs
por: Fourie, Josephus J., et al.
Publicado: (2019) -
Comparative speed of kill after treatment with Simparica(™)(sarolaner) and Advantix(®)(imidacloprid + permethrin) against induced infestations of Dermacentor reticulatus on dogs
por: Becskei, Csilla, et al.
Publicado: (2016) -
Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe
por: Becskei, Csilla, et al.
Publicado: (2020) -
Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs
por: Becskei, Csilla, et al.
Publicado: (2020)